National Center for Advancing Translational Sciences; Notice of Closed Meeting, 18577 [2020-06870]

Download as PDF 18577 Federal Register / Vol. 85, No. 64 / Thursday, April 2, 2020 / Notices ANNUAL BURDEN ESTIMATES Total number of respondents Instrument State Plan (OCSE–100) .................................................................................. State Plan Transmittal (OCSE–21–U4) ........................................................... jbell on DSKJLSW7X2PROD with NOTICES 54 54 Estimated Total Annual Burden Hours: 486. and Research Training, National Institutes of Health, HHS) (Authority: Sections 452, 454, and 466 of the Social Security Act) Mary B. Jones, ACF/OPRE Certifying Officer. Dated: March 27, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–06869 Filed 4–1–20; 8:45 am] [FR Doc. 2020–06870 Filed 4–1–20; 8:45 am] BILLING CODE 4184–41–P BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Center for Advancing Translational Sciences; Notice of Closed Meeting Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel CTSA. Date: May 8, 2020. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual and Teleconference Meeting). Contact Person: Victor Henriquez, Ph.D., Scientific Review Officer, Office of Scientific Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 20892–4878, 301–435–0813 henriquv@ mail.nih.gov, (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research VerDate Sep<11>2014 18:34 Apr 01, 2020 Jkt 250001 AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Lyell Immunopharma, Inc. (‘‘Lyell’’), located in South San Francisco, CA. SUMMARY: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before April 17, 2020 will be considered. DATES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702; Telephone: (240) 276–5484; Facsimile: (240) 276–5504; Email: andy.burke@nih.gov. ADDRESSES: SUPPLEMENTARY INFORMATION: PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 Total number of responses per respondent Average burden hours per response 12 12 Total burden hours .5 .25 324 162 Intellectual Property Group A E–022–2017: Methods for Selecting Therapy for a Cancer Patient 1. US Provisional Patent Application 62/418,461 filed November 7, 2016 (E– 022–2017–0–US–01); 2. International Patent Application PCT/US2017/060304 filed November 7, 2017 (E–022–2017–0–PCT–02); 3. European Patent Application 17805342.7 filed May 6, 2019 (E–022– 2017–0–EP–03); and 4. United States Patent Application 16/347,778 filed May 6, 2019 (E–022– 2017–0–US–04). Group B E–250–2016: Methods of Preparing an Isolated or Purified Population of Thymic Emigrant Cells and Methods of Treatment Using the Same 1. US Provisional Patent Application 62/433,591 filed December 13, 2016 (E– 250–2016–0–US–01); 2. International Patent Application PCT/US2017/065986 filed December 13, 2017 (E–250–2016–0–PCT–02); 3. European Patent Application 17825696.2 filed June 11, 2019 (E–250– 2016–0–EP–03); and 4. United States Patent Application 16/468,890 filed June 12, 2019 (E–250– 2016–0–US–04). E–132–2017: Methods of Preparing Hematopoietic Progenitor Cells In Vitro 1. US Provisional Patent Application 62/583,240 filed November 8, 2017 (E– 132–2017–0–US–01); and 2. International Patent Application PCT/US2018/059856 filed November 8, 2018 (E–132–2017–0–PCT–02). E–133–2017: In Vitro Generation of Thymic Organoid From Human Pluripotent Stem Cells 1. US Provisional Patent Application 62/560,908 filed September 20, 2017 (E– 133–2017–0–US–01); and 2. International Patent Application PCT/US2018/051625 filed September 19, 2018 (E–133–2017–0–PCT–02). E:\FR\FM\02APN1.SGM 02APN1

Agencies

[Federal Register Volume 85, Number 64 (Thursday, April 2, 2020)]
[Notices]
[Page 18577]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06870]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel CTSA.
    Date: May 8, 2020.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, One Democracy Plaza, 6701 
Democracy Boulevard, Bethesda, MD 20892 (Virtual and Teleconference 
Meeting).
    Contact Person: Victor Henriquez, Ph.D., Scientific Review 
Officer, Office of Scientific Director, National Center for 
Advancing Translational Sciences (NCATS), National Institutes of 
Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 
20892-4878, 301-435-0813 [email protected],

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)

    Dated: March 27, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-06870 Filed 4-1-20; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.